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Abstract
Background: Runt-related transcription factor 3 (RUNX3) is a member of the runt-domain family of transcription
factors and has been reported to be a candidate tumor suppressor in gastric cancer. However, the association
between RUNX3 promoter methylation and gastric cancer remains unclear.
Methods: We systematically reviewed studies of RUNX3 promoter methylation and gastric cancer published in
English or Chinese from January 2000 to January 2011, and quantified the association between RUNX3 promoter
methylation and gastric cancer using meta-analysis methods.
Results: A total of 1740 samples in 974 participants from seventeen studies were included in the meta-analysis. A
significant association was observed between RUNX3 promoter methylation and gastric cancer, with an aggregated
odds ratio (OR) of 5.63 (95%CI 3.15, 10.07). There was obvious heterogeneity among studies. Subgroup analyses
(including by tissue origin, country and age), meta-regression were performed to determine the source of the
heterogeneity. Meta-regression showed that the trend in ORs was inversely correlated with age. No publication
bias was detected. The ORs for RUNX3 methylation in well-differentiated vs undifferentiated gastric cancers, and in
intestinal-type vs diffuse-type carcinomas were 0.59 (95%CI: 0.30, 1.16) and 2.62 (95%CI: 1.33, 5.14), respectively.
There were no significant differences in RUNX3 methylation in cancer tissues in relation to age, gender, TNM stage,
invasion of tumors into blood vessel or lymphatic ducts, or tumor stage.
Conclusions: This meta-analysis identified a strong association between methylation of the RUNX3 promoter and
gastric cancer, confirming the role of RUNX3 as a tumor suppressor gene.
Background
Gastric cancer is the second most common gastrointest-
inal tumor worldwide. Although its incidence continues
to decline year by year, it remains the second most
common causes of cancer-related deaths [1,2].
Runt-related transcription factor 3 (RUNX3) is a
member of the runt domain family of transcription fac-
tors, also known as polyomavirus enhancer-binding pro-
tein 2 (PEBP2)/core binding factors (CBF) [3-5]. RUNX3
is a known regulator of major developmental pathways,
and has recently been reported as a candidate tumor
suppressor [3-5]. RUNX3 is located on human chromo-
some region 1p36 and plays an important role in the
transforming growth factor (TGF)-b signaling pathway.
This may occur partly through interaction with FoxO3a/
FKHRL1, both of which are indispensable for the activa-
tion of the pro-apoptosis protein Bim (Bcl-2-interacting
mediator of cell death), or by cooperating with SMAD
protein family members to induce the TGF-b/SMAD
pathway in other ways [6,7]. The RUNX3 gene is regu-
lated by three main mechanisms: loss of heterozygosity
(LOH), protein mislocalization, and promoter methyla-
tion [3,5,8,9]. Silencing of the promoter region CpGs of
regulated genes via hypermethylation is recognized as
one of the mechanisms responsible for loss-of-gene-
function in Knudson’s two-hit tumor progression
hypothesis[10]. Numerous studies using cell lines,
knockout animals, and primary human cancer samples
have demonstrated a crucial role for RUNX3 not only in
normal development, but also in neoplasias, especially
stomach cancers [3,5,11]. Previous studies have reported
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many cancers, including colorectal [12,13], gastric [14],
bladder [15], breast [16], lung [17], oral [18], and naso-
pharyngeal cancers [19]. However, the role of RUNX3 in
the regulation of gastric epithelial cell growth and its
tumor suppressor activity in gastric cancer remain to be
clarified. Levanon and colleagues questioned the causal
relationship between loss of RUNX3 expression and gas-
tric cancer, and reported that RUNX3-deficient mice did
not develop gastric hyperplasia or gastric tumors
[20,21]. Carvalho et al. refuted a tumor suppressor role
for the RUNX3 gene in early-onset gastric carcinomas,
on the basis of its lack of expression in histological non-
neoplastic gastric epithelium, although at least two
copies of the gene were present in the vast majority of
cells analyzed [22]. However, associations between
RUNX3 promoter methylation and gastric cancer have
mostly been investigated in studies with small sample
sizes, low statistical power, specific ethnic backgrounds,
or other limitations in study design, leading to conflict-
ing results.
Meta-analysis is a well-established method for quanti-
fying gene-disease associations more precisely, by using
all the available published data to increase the statistical
power [23]. We therefore conducted a meta-analysis
using all available related studies to better define the
association between RUNX3 promoter methylation and
gastric cancer.
Methods
Search strategy
This pooled study involved searching a range of compu-
terized databases, including Medline, Blackwell,
Cochrane Central, Web of Science, and Ovid, for articles
published in English or Chinese from January 2000 to
January 2011. The study used a subject and text word
strategy with (RUNX3 OR AML2 OR CBFA3 OR PEBP)
AND ((gastric OR stomach) AND (cancer OR neo-
plasm)) as the primary search terms. The search strategy
was tailored to each database to ensure that the search
was comprehensive and not limited to randomized con-
trolled trials.
Selection of studies and data extraction
Three independent reviewers (Fan, Hu and Pan)
screened the titles and abstracts identified by the elec-
tronic search to identify relevant studies. Relevant arti-
cles were further examined to see if they met the
inclusion criteria. The reference sections of all retrieved
articles were searched to identify further relevant arti-
cles. A citation search was carried out on all included
articles using the Science Citation Index. Potentially
relevant papers were obtained and the full text articles
were screened for inclusion by two independent
reviewers (Fan, Hu). Disagreements were resolved by
discussion. Included studies were summarized in data
extraction forms. Authors were contacted when relevant
data were missing.
The name of the first author, year of publication, ori-
gin of the study patients, sample size, and methylation
status of the RUNX3 promoter in human gastric cancer
and normal or control tissues were extracted. The inclu-
sion criteria were as follows: the patients had to be diag-
nosed with gastric cancer and the studies had to have
RUNX3 gene promoter methylation data from tissue
samples. The following types of studies were excluded:
animal experiments, case reports, review articles or
meta-analyses, and studies with insufficient data.
Data analysis and synthesis
Data were analyzed mainly using STATA Software
(Stata/SE 11.0 for Windows, StataCorp LP). The
strength of association was expressed as pooled odds
ratio (OR) with corresponding 95% confidence intervals
(CI). Data were extracted from the original studies and
recalculated if necessary. The data were pooled using
the DerSimonian and Laird random effects model [24],
which takes account of both within-study and between-
study variations. A two-sided P ≤ 0.05 was considered
significant. Heterogeneity was tested using the I
2 statis-
tic with values >50% and c
2 test with P ≤ 0.05 indicating
strong heterogeneity between the studies. τ
2 was used to
determine how much heterogeneity was explained by
subgroup differences [25]. If the heterogeneity was sig-
nificant, Galbraith plot and meta-regression analyses
were employed to analyze the sources of the heterogene-
ity. Subgroup analyses of the ORs of RUNX3 promoter
methylation in cancer tissue versus normal tissue were
performed according to control types (autogenous and
heterogeneous), patient origins (Europe-America, China,
Japan, and Korea) and age categories (<60, between 60
and 65, and ≥65). Sensitivity analyses were performed to
assess the contributions of single studies to the final
results. Possible bias was analyzed by funnel plot. If bias
was suspected, the meta-trim method was used to re-
estimate the effect size. Differences in methylation status
of cancer tissues were also analyzed in relation to age
(≤60, >60), gender (male, female), metastases, and histo-
pathological cancer type.
Results
Study characteristics
The electronic search strategy identified 132 potentially
relevant articles, which were further screened for inclu-
sion on the basis of their titles, abstracts, full texts, or a
combination of these. The electronic search was supple-
mented from reference lists of relevant articles including
reviews, and by discussion with experts.
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38 were excluded. The remaining 17 studies included
data on the relationship between RUNX3 gene promoter
methylation and gastric cancer, and these studies were
pooled for analysis (Table 1) [14,26-41]. Sixteen of the
included articles were written in English, and one was
written in Chinese. The main characteristics of each
study are shown in the supplementary data (Table 1).
Among the 17 retrieved articles, 16 observations in 15
studies used methylation-specific polymerase chain reac-
tion to explore RUNX3 promoter methylation in gastric
cancer tissues (n = 928) and normal tissues (n = 812),
with a total sample size of 1740 cases. The total number
of participants is 974 from 17 articles including 890
patients from 17 articles and 84 controls from 3 articles
which provided heterogeneous control groups. The
pooled OR for RUNX3 methylation in cancer tissues
compared with normal tissues was 5.63 (95%CI 3.15-
10.06, z = 5.82, P < 0.0001), indicating an increased like-
lihood of methylation in gastric cancer tissue, compared
with normal tissue (Figure 1).
Subgroup analysis and meta-regression
The OR in the autologous tissue subgroup was 6.42 (95%
CI: 4.07, 10.11; P < 0.0001) and that in the heterogeneous
tissue subgroup was 4.44 (95%CI: 0.35, 56.70; P = 0.251)
(Table 2). Tissue subgroup analysis showed that the inci-
dence of methylation in autologous cancer tissues was
higher than that in normal tissues, but there was no
obvious difference between autologous and heteroge-
neous tissues. The difference was not deemed significant
by the random effects method, because of the existing
heterogeneity (I
2 = 89.30%, c
2 = 18.69; P < 0.0001) (Table
2). The OR for the Japanese subgroup was 3.20 (95%CI:
1.60, 6.39; P = 0.001), for the European-American sub-
group was 5.15 (95%CI: 0.23, 113.17; P = 0.251), for the
Chinese subgroup was 26.19 (95%CI: 8.04, 85.33; P <
0.0001), and for the Korean subgroup was 4.96 (95%CI:
2.14, 11.47; P < 0.0001) (Table 2, Figure 1). Heterogeneity
also existed within patients of each origin, especially in
the European-American subgroup (I
2 = 83.20%, c
2 =
5.95; P = 0.015), which changed the OR from significant
(fixed) to non-significant (random) (Table 2, Figure 1).
The OR for the age <60 group was 15.00 (95%CI: 5.21,
43.15; P < 0.0001), that for the 60-65 subgroup was 6.31
(95%CI: 3.19, 12.46; P < 0.0001), and that for the ≥65
subgroup was 3.75 (95%CI: 1.29, 10.89; P = 0.015) (Table
2, Figure 1).
Heterogeneity existed in all studies (I
2 = 74.10%, c
2 =
57.91, P < 0.0001) (Table 2). We therefore performed
further analyses using the meta-regression method with
the Knapp-Hartung modification. The restricted maxi-
mum likelihood method was used to estimate between-
study variance.
The results of meta-regression indicated that the trend
in ORs was inversely correlated with age, which
accounted for some of the heterogeneity (coefficient =
-0.16, P = 0.042, adjusted R
2 = 44.47%, Table 3). How-
ever, other factors such as sample size, year of publica-
tion, proportion of males, and the origin of the patients
could not explain the heterogeneity (Table 3).
Bias analysis and robust estimation of pooled OR
A funnel plot of methylation status of gastric cancer tis-
sue versus normal tissue showed that four studies
exceeded the 95% confidence limits (Figure 2). We also
performed sensitivity analyses to determine the effects
of omitting a single study on the overall effect; omission
of a single study changed the overall OR from 5.15
(2.85, 9.29) to 6.09 (3.37, 11.0) using the random
method, suggesting that there was no single sensitive
study (Table 4). Trim and fill analysis was performed
using the random effects model. The pooled OR was
4.67 (95%CI: 2.57, 8.49; P < 0.0001) indicating a positive
association between RUNX3 methylation and gastric
cancer.
Comparators in cancer tissue
There were no significant differences in RUNX3 methy-
lation status in cancer tissue in relation to age, gender,
TNM stage, invasion of tumors into blood vessels or
lymphatic ducts, or tumor stage, or tumor metastases
(Data not shown).
The overall results demonstrated that RUNX3 methy-
lation was more frequent in intestinal-type, compared
with diffuse-type gastric carcinomas (OR = 2.62, 95%CI:
1.33, 5.14). Undifferentiated gastric cancer also had a
higher methylation OR than well-differentiated cancer
tissue (OR = 0.59, 95%CI: 0.30, 1.16) (Data not shown).
Discussion
The role of the RUNX3 gene in gastric cancer is contro-
versial [3,20,22,42,43]. Inactivation of the RUNX3 gene
can be caused by LOH, promoter hypermethylation, or
protein mislocalization. Methylation of the RUNX3 pro-
moter is one of the most common aberrant methylation
events in cancer [44]. We therefore performed a meta-
analysis to quantify the association between RUNX3
promoter methylation and gastric cancer.
The overall OR for methylation status in gastric can-
cer versus normal gastric tissue was 5.63 (3.15, 10.07),
using a random effects model on pooled data from 16
observations in 15 studies. Subgroup analysis showed
an OR in the heterogeneous tissue-origin subgroup of
4.44 (0.35, 56.70), which was significant in the fixed,
but not in the random effects model. This discrepancy
may be a result of the smaller number of studies ana-
lyzed. The ORs also differed in subgroups with
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Study/Country Mean/median
age (range)
(years)
Gender
(M/F)
Patients
(M+/M-)
Control
(M+/M-)
Methods Primary Aim Methylation site RUNX3
Expression
Waki et al
(2003)[26]/
Japan
64.3 (0.7-89) 68/25 42/51 7/86A 4/
15H
MSP, RT-
PCR
Clarify the physiological
consequence of DAP-kinase and
RUNX3 age-related methylation in
gastric epithelia
CpG islands +
Oshimo et al
(2004)[14]/
Japan
68.8 (38-87) 56/24 57/23 38/7H MSP, qRT-
PCR
Loss of RUNX3 expression by
promoter hypermethylation in
Gastric Carcinoma
CpG islands +
Nakase et al
(2005)[27]/
Japan
65.4 81/32 14/8 6/16A MSP, qRT-
PCR
Determine whether alteration of
RUNX3 gene expression could be
detected in the normal-looking
gastric remnant mucosa stomach
after distal gastrectomy for peptic
ulcer or gastric cancer
promoter
hypermethylation
+
Homma et al
(2006)[28]/USA
63 (30-85) 28/17 43/2 43/2A MSP Clarify how methylation spreads
within the CpG island
region NO.1 at
CpG islands
-
So et al (2006)
[29]/Japan
64 (30-82) 17/9 11/5 6/20A MSP,
microarray
Use microarray-based methylation
assay to assess gene methylation
CpG islands -
Mitsuno et al
(2007)[30]/
Japan
63.2 (26-86) 29/9 18/20 Not
reported
MSP Determine whether DNA methylation
in six cancer-related genes affects
recurrence of gastric cancer in
patients who received 5-fluorouracil-
based adjuvant chemotherapy
CpG islands -
Gargano et al
(2007)[31]/Italy
Not reported 65/35 22/18 2/38A MSP Investigate a possible relationship
between the RUNX3 promoter
methylation, nuclear microsatellite
instability and mitochondrial
microsatellite instability
CpG islands -
Fujii et al
(2008)[32]/
Japan
62.8 (52-77) 8/9 11/6 Not
reported
MSP, ChIP,
RT-PCR
Enhancer of Zeste Homologue 2
(EZH2) down-regulates RUNX3 by
increasing histone H3 methylation
CpG islands +
Kitajima et al
(2008)[33]/
Japan
65.71 34/23 30/27 10/47A MSP, PCR Determine the Helicobacter pylori
infection as an independent risk
factor for Runx3 methylation in
gastric cancer
CpG islands +
Li et al (2008)
[34]/China
62 (35-78) 23/17 22/18 0/40A MSP Analyze the relationships among the
aberrant methylation of RUNX3 gene
promoter, the RUNX3 protein
expression and clinicopathological
features in gastric cancer
CpG islands +
Song et al
(2008)[35]/
Korea
64 50/29 26/53 9/70A MSP Determine the methylation of RUNX3
promoter and the association
between RUNX3 methylation and
the clinicopathological characteristics
of patients with gastric carcinoma
CpG islands -
KIM et al
(2009)[36]/
Republic of
Korea
57.7 53/21 18/56 2/61A MSP Comparison of DNA methylation
between primary and metastatic
gastric carcinoma
promoter -
Zou et al
(2009)[37]/
China
65.15 40/17 14/2 0/20H MSP Determine the methylation
frequency of 5 genes, including p16,
Runx3, MGMT, DAPK, and RASSF1A
CpG islands +
Chen et al
(2010)[38]/
China
53 (20-78) 20/50 28/42 2/68A MSP, RT-
PCR
Hypermethylation downregulates
Runx3 gene expression and its
restoration suppresses gastric
epithelial cell growth by inducing
p27 and caspase3 in human gastric
cancer
CpG islands +
Hiraki et al
(2010)[39]/
Japan
68.6 (45-88) 30/19 28/21 14/35A q-MS,
qRT-PCR
Determine whether gene
methylation is a novel diagnostic
marker for micrometastasis to the
lymph nodes (LNs) in gastric cancer
Promoter
hypermethylation
+
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Hu et al (2010)
[40]/China
64.1 97/26 68/55 12/111A MSP, RT-
PCR
Pathobiologic implications of
methylation and expression status of
Runx3 and CHFR genes in gastric
cancer
CpG islands +
Mikata et al
(2010) [41]/
Japan
70 (56-85) 14/7 10/11 4/17A MS, qRT-
PCR, RT-
PCR
BCL2L10 hypermethylation in gastric
cancer and its correlation with
RUNX3
CpG islands -
A: Autologous control, the control tissues from the patients themselves; H: Heterogeneous control, the control tissues from other individuals. M+: The number of
tissues with methylation; M-: The number of tissues with unmethylation.
Figure 1 Forest plot of RUNX3 promoter methylation in cancer tissue vs normal tissue and subgroup analyses.
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group was 26.19 (95%CI: 8.04, 85.33), followed by the
European-American subgroup (OR = 5.15, 95%CI:
0.23, 113.17), the Korean subgroup (OR = 4.96, 95%CI:
2.14, 11.47), and the Japanese subgroup (OR = 3.20,
95%CI: 1.60, 6.39). The ORs for the different age sub-
groups were 15.00 (95%CI: 5.21, 43.15) for age <60,
6.31 (95%CI: 3.19, 12.46) for age 60-65, and 3.75 (95%
CI: 1.29, 10.89) for age ≥ 65. Heterogeneity within the
studies was demonstrated by c
2and I
2 tests and meta-
regression was therefore used to determine the sources
of the heterogeneity. This showed that the trend in
ORs was inversely correlated with age, which
accounted for at least some of the heterogeneity (coef-
ficient = -0.16, P = 0.042, adjusted R
2 =4 4 . 4 7 % ) .
These results were consistent with the results of sub-
group analysis according to age. The incidence of age-
related methylation in most organs was in accordance
with the reported incidences of methylation in their
malignant counterparts [45]. RUNX3 methylation was
reported to occur preferentially in the lower third por-
tion of the stomach in individuals older than 70 years
[45]. We found that the ORs for RUNX3 methylation
decreased from 15.00 in the younger age group,
through 6.31, to 3.75 in the oldest age group. The
coefficient for age was calculated to be -0.16 by meta-
regression analysis, indicating that the tendency for
RUNX3 methylation decreased with advancing age. To
the best of our knowledge, the current study is the
first to report this finding. However, there was no sig-
nificant difference in RUNX3 promoter methylation
status of cancer tissues between older (more than 60)
and younger (less than 60) individuals. This suggests
that RUNX3 methylation was not correlated with age
in gastric cancer tissue. However, in accordance with
the previous study, RUNX3 methylation did decrease
Table 2 Subgroup analysis
Group Cancer Normal Sum M-H pooled OR D+L pooled OR Heterogeneity τ
2
M+ N M+ N OR (95%CI) z p OR(95%CI) z P c
2 I
2 (%) P
Total 475 928 159 812 1740 5.52(4.30, 7.10) 13.3 < 0.0001 5.63
(3.15,10.07)
5.82 < 0.0001 57.91 74.1 < 0.0001 0.94
Tissue subgroup
Autologous tissue 362 739 117 728 1467 7.15(5.36, 9.53) 13.4 < 0.0001 6.42
(4.07,10.11)
8 < 0.0001 24.12 50.02 0.02 0.32
Heterogeneous
tissue
113 189 42 84 273 5.52(4.30, 7.10) 2.22 0.026 4.44
(0.35,56.70)
1.15 0.251 18.69 89.3 < 0.0001 4.21
Origin subgroup
Japan 234 441 89 332 773 3.20(2.30, 4.47) 6.86 < 0.0001 3.20(1.60,6.39) 3.29 0.001 25.03 72 0.001 0.7
Euro-America 65 85 45 85 170 8.12(2.76,
23.88)
3.8 < 0.0001 5.15
(0.23,113.17)
1.04 0.299 5.95 83.2 0.015 4.14
China 132 249 14 253 502 18.44
(10.30, 33.03)
9.8 < 0.0001 26.19
(8.04,85.33)
5.42 < 0.0001 5.82 48.4 0.121 0.66
Korea 44 153 11 142 295 5.10(2.48,
10.47)
4.42 < 0.0001 4.96
(2.14,11.47)
3.74 < 0.0001 1.18 15.5 0.277 0.07
Age subgroup
age < 60 46 114 4 133 247 15.25(5.33,
43.61)
5.08 < 0.0001 15.00
(5.21,43.15)
5.02 < 0.0001 0.6 < 0.001 0.437 < 0.001
60≤age < 65 276 539 83 465 1004 7.41(5.16,
10.62)
10.9 < 0.0001 6.31
(3.19,12.46)
5.3 < 0.0001 18.88 62.9 0.009 0.54
age≥65 153 245 72 214 459 2.93(1.98, 4.32) 5.39 < 0.0001 3.75
(1.29,10.89)
2.43 0.015 25.18 80.1 < 0.0001 1.31
M+: The number of tissues with methylation; N: Number of the total observations.
Table 3 Meta-regression
Sources Coefficient (95%CI) t P τ
2 I
2 Res (%) Adjusted R
2 (%)
Sample size -0.01 (-0.03, 0.01) -1.04 0.314 1.07 75.33 -7.96
Year of publication 0.19 (-0.07, 0.46) 1.54 0.145 0.90 71.95 9.9
Proportion of males -2.91 (-9.67, 3.84) -0.93 0.370 1.03 75.5 -3.89
Control type -1.06 (-2.87, 0.76) -1.25 0.233 0.70 65.97 29.99
Age -0.16 (-0.31, -0.01) -2.22 0.042 0.52 63.91 44.47
Origin of the patients -0.57 (-1.16, 0.03) -2.05 0.060 0.66 66.74 33.92
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negative correlation between RUNX3 methylation and
age suggests that the influence of RUNX3 methylation
on gastric cancer is reduced in older individuals.
Other factors including sample size, year of publica-
tion, proportion of males, and the origins of the patients
were not identified as sources of heterogeneity by meta-
regression analysis.
Meta-analysis of small studies may result in biased
results. The funnel plot showed that the standard errors
in four of the studies exceeded the 95% confidence
limits; furthermore, the asymmetry test of the funnel
plot by Egger’s regression method showed that the smal-
ler studies reported more positive results, raising the
suspicion of bias among the studies. To produce a more
robust estimation, we performed sensitivity analysis
using the random effects model and were unable to
identify any individual sensitive study with a strong
influence on the pooled results. Trim and fill tests were
performed using the random effects model, and two vir-
tual studies were filled. The overall OR of the trim and
fill method was 4.67, which was slightly smaller than
that of the crude meta-analysis, but it was still signifi-
cant, indicating a strong association between RUNX3
promoter methylation and gastric cancer.
There were no significant differences in RUNX3
methylation in cancer tissues in relation to gender,
TNM stage, invasion of tumors into vessels or lympha-
tic ducts, or tumor stage. Although some studies have
reported significant differences in methylation status
and protein expression of RUNX3 in relation to tumor
invasion depth [46], the overall results of the current
study failed to support the existence of such a relation-
ship. Previous studies have also reported increased
methylation of RUNX3 in stage I and II gastric can-
cers, suggesting that the RUNX3 gene contributes to
gastric cancer development [38]. However, the results
of the current meta-analysis did not support this
assumption. Other factors, such as tumor invasion of
blood vessels, lymph nodes or lymphatic ducts, and
tumor metastases, also demonstrated no relation with
RUNX3 methylation.
The aggregated results found that RUNX3 methylation
was more frequent in intestinal-type compared with dif-
fuse-type gastric carcinomas, suggesting that inactivation
of RUNX3 might play a more significant role in the
development of intestinal-type gastric carcinomas.
Analysis of the pooled data also showed that undiffer-
entiated gastric cancers had a higher methylation OR
than well-differentiated cancer tissues. This suggests
that RUNX3 promoter methylation or down-regulation
of the RUNX3 gene may be related to poor prognosis,
as suggested in previous studies [47,48].
Conclusions
In conclusion, this meta-analysis of pooled data provides
additional evidence to support a strong association
between methylation of the RUNX3 promoter and gas-
tric cancer. This association depended on patient origin
and the controls used, and further studies are needed to
explore these aspects. Younger individuals had higher
RUNX3 methylation rates than older individuals.
RUNX3 methylation was also associated with histologi-
cal type and differentiation state of the gastric cancer.
However, gender, TNM stage, invasion of tumors into
Figure 2 Funnel plot. The results of the funnel plot showed that
the standard errors in four of the studies exceeded the 95%
confidence limit, and the Egger’s regression line showed that the
smaller studies tend to report more positive association of RUNX3
promoter methylation with gastric cancer but was not significant (P
= 0.593).
Table 4 Sensitivity analysis
Study omitted Estimate OR 95% CI
Lower Upper
Waki(a) (2003) 5.40 2.90 10.06
Waki(b) (2003) 5.92 3.19 10.98
Oshimo (2004) 6.55 4.12 10.43
Nakase (2005) 5.74 3.09 10.66
Homma (2006) 6.09 3.37 11.00
So (2006) 6.00 3.25 11.08
Gargano (2007) 5.16 2.85 9.32
Kitajima (2008) 5.74 3.03 10.86
Li (2008) 5.15 2.90 9.14
Song (2008) 5.89 3.12 11.13
Kim (2009) 5.46 2.97 10.04
Zou (2009) 5.08 2.89 8.93
Hu (2010) 5.30 2.86 9.83
Chen (2010) 5.15 2.85 9.29
Hiraki (2010) 5.95 3.16 11.20
Mikata (2010) 5.80 3.14 10.73
Combined 5.63 3.15 10.06
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showed no significant associations with RUNX3 methy-
lation in gastric cancer tissues.
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